about
Multidrug resistance-associated protein 4 (MRP4) gene polymorphisms and treatment response in adult acute lymphoblastic leukemiaMolecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials.Clinical features and prognostic implications of TCF3-PBX1 and ETV6-RUNX1 in adult acute lymphoblastic leukemiaInternational reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia.Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.The European LeukemiaNet: achievements and perspectives.Low expression of T-cell transcription factor BCL11b predicts inferior survival in adult standard risk T-cell acute lymphoblastic leukemia patientsLiposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphoma.FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitorsImproved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trialTargeted therapies in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.Risk-adapted treatment according to minimal residual disease in adult ALL.Mutational spectrum of adult T-ALLTreatment with monoclonal antibodies in acute lymphoblastic leukemia: current knowledge and future prospects.Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment.Novel antibody-based therapy for acute lymphoblastic leukaemia.Treatment of adult acute lymphoblastic leukemia.CD56 expression in T-cell acute lymphoblastic leukemia is associated with non-thymic phenotype and resistance to induction therapy but no inferior survival after risk-adapted therapyT-cell lymphoblastic lymphoma and T-cell acute lymphoblastic leukemia: a separate entity?Chemoimmunotherapy in acute lymphoblastic leukemia.Acute lymphoblastic leukemia: monitoring minimal residual disease as a therapeutic principle.Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL[Leukemia research in Germany: the Competence Network Acute and Chronic Leukemias].[Focus on academic multicenter trials: impact of the German drug law on hematological/oncological therapy optimization trials].Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab.Clinical applications and safety evaluation of the new CD19 specific T-cell engager antibody construct blinatumomab.Treatment of older patients with acute lymphoblastic leukemia.Philadelphia-Like Acute Lymphoblastic Leukemia in Adults.How I treat older patients with ALL.Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies.Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.Erroneous class switching and false VDJ recombination: molecular dissection of t(8;14)/MYC-IGH translocations in Burkitt-type lymphoblastic leukemia/B-cell lymphoma.Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81 patients.Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia.Loss-of-function but not dominant-negative intragenic IKZF1 deletions are associated with an adverse prognosis in adult BCR-ABL-negative acute lymphoblastic leukemia.Germline variants in IKZF1, ARID5B, and CEBPE as risk factors for adult-onset acute lymphoblastic leukemia: an analysis from the GMALL study group.Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia.Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib.The role of high-dose cytarabine in induction therapy for adult ALL.Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia.
P50
Q28268027-95F80AD5-E39D-4486-AAE1-389FD5707673Q31064796-ECB1D591-D236-4980-B8D8-91D1838EE3B7Q33632230-3B71796D-D9D7-4D01-8F47-9082789AA576Q33822004-7D3CB408-B906-46E9-B7FB-EEF5548BC55DQ34042800-1C8075DE-345E-40A1-85B8-75078F258F7EQ34451619-A6279559-8043-48F0-A7B0-361F6C83F082Q34469099-32DAB6D4-DD39-4E8E-BDB4-53100353C5D0Q34543015-03F1DDEC-7EA8-45DD-944F-7623E62F9121Q34566158-472D8F0D-4B1E-49CA-8E3A-950B6EF126BFQ34737471-B9EA3F23-53D2-4FE4-BA7E-84D39D011C7BQ35007256-3AB67607-6747-4161-B606-F70D80F39A99Q35078296-DBD5F469-A6C7-41F0-A578-22BE674BEFB9Q35550090-41EB28DF-51AC-41E9-B8A9-9C40A67DE3E9Q35597259-67EBC5BA-0822-41CB-AFC3-267076CD381FQ36350443-59023FB1-1383-4D7F-8E25-517FA23B7AE1Q36602041-6396D1E9-6677-4AF6-A8D1-863B0A51C72FQ36662137-D82832AA-7344-4B68-A8EE-2A862E66BD54Q37082729-A5164422-4773-4504-90BE-4BCBEECC8914Q37602871-61651126-0EF2-4AF4-AF4A-9159C1F620C8Q37940656-960B3797-BB8D-4933-A145-CD4EDB30BD1DQ37979956-BF476527-1C82-435A-AA4B-E118886F7435Q38376489-8AF9A78C-B320-49A1-B878-1922EB759BC3Q38382105-765B8F80-37CF-4DFD-B8D2-C90427959D93Q38409064-0BD5A45F-DB02-4360-B058-6F02C78151CCQ38471537-D4ED89E4-8CB8-4DEB-9473-328FC306ADD0Q38639698-5D54BA55-D132-4F56-9FDF-F2D4DBA26642Q38787763-DB64BE9D-4FFC-49E7-9B9E-0A8068020C4DQ39210250-DBF123B4-BFBA-430B-8888-C24BC504EAB6Q39419031-F1DFFC26-6C7E-4945-819D-9B2F97D7D50CQ39796888-7F812584-ABC3-48C6-981C-B86FAF99C15BQ40705613-F3B2FFDC-3975-4F2A-B515-C2F5FF80456DQ41134120-D3B933ED-CFE1-4EF8-8C30-91C0441F3306Q42244747-177B8853-AF9A-4381-9764-1605645B40B4Q42361917-EE142C94-971E-410D-B6DB-C6184ADA350EQ42368324-8DDF4310-1620-4C01-97C7-40A6DCC7A942Q42632052-A40DA79A-94D9-4D48-835F-3796C0F39F18Q43457128-BEC01FD6-E62F-4ED6-BECE-50E9104989F2Q43473669-640C892E-8605-4482-B0E4-84BE70E5D6CDQ43935093-9E65E596-5EE4-491D-A271-01982EE85EBAQ44010380-E2CEE233-9521-4764-8707-7431A2D8E8C6
P50
name
Nicola Gökbuget
@ast
Nicola Gökbuget
@en
Nicola Gökbuget
@fr
Nicola Gökbuget
@nl
type
label
Nicola Gökbuget
@ast
Nicola Gökbuget
@en
Nicola Gökbuget
@fr
Nicola Gökbuget
@nl
prefLabel
Nicola Gökbuget
@ast
Nicola Gökbuget
@en
Nicola Gökbuget
@fr
Nicola Gökbuget
@nl
P214
P214
P31
P735
P7859
viaf-210031297